BioImpact Capital LLC, 10% Owner at Cullinan Oncology, Inc. (CGEM), sold 97,280 shares at $29.60 ($2.8M) on 2021-09-03, disclosed to the SEC on 2021-09-08.
Scheduled sale ($2.8M) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.60 | 12,731 | $377K | 13.3% |
| 2 | $29.60 | 12,731 | $377K | 13.3% |
| 3 | $29.04 | 25,067 | $728K | 25.6% |
| 4 | $29.04 | 25,067 | $728K | 25.6% |
| 5 | $29.11 | 10,842 | $316K | 11.1% |
| 6 | $29.11 | 10,842 |
| $316K |
| 11.1% |
| Total | $29.20 avg | 97,280 | $2.8M | 100% |
| Filing → |
| CGEM | SELL | 2021-09-20 | $182K | — | Filing → |
| CGEM | SELL | 2021-09-16 | $602K | — | Filing → |
| CGEM | SELL | 2021-09-13 | $1.4M | — | Filing → |